Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline

Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases Vol. 71; no. 4; p. e1
Main Authors: Daley, Charles L, Iaccarino, Jonathan M, Lange, Christoph, Cambau, Emmanuelle, Wallace, Jr, Richard J, Andrejak, Claire, Böttger, Erik C, Brozek, Jan, Griffith, David E, Guglielmetti, Lorenzo, Huitt, Gwen A, Knight, Shandra L, Leitman, Philip, Marras, Theodore K, Olivier, Kenneth N, Santin, Miguel, Stout, Jason E, Tortoli, Enrico, van Ingen, Jakko, Wagner, Dirk, Winthrop, Kevin L
Format: Journal Article
Language:English
Published: United States 14.08.2020
Subjects:
Adult
Humans
Mycobacterium abscessus
Mycobacterium avium Complex
Mycobacterium Infections, Nontuberculous - diagnosis
Mycobacterium Infections, Nontuberculous - drug therapy
Mycobacterium Infections, Nontuberculous - epidemiology
Mycobacterium kansasii
Nontuberculous Mycobacteria
Mycobacterium avium complex
Mycobacterium xenopi
nontuberculous
Mycobacterium abscessus
Mycobacterium kansasii
ISSN:1537-6591, 1537-6591
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Instructional Material/Guideline-3
content type line 23
ISSN:1537-6591
1537-6591
DOI:10.1093/cid/ciaa241